Royalty Pharma has agreed to provide up to $500 million to support Teva’s anti-IL-15 candidate, TEV-‘408, which is currently in Phase 1b for vitiligo and Phase 2a for celiac disease. This funding agreement aligns with Teva’s Pivot to Growth strategy to accelerate pipeline development and bring treatments to patients faster. Royalty Pharma will contribute $75 million for Phase 2b funding, with an option for an additional $425 million. TEV-‘408 is an investigational human monoclonal antibody designed to inhibit interleukin-15 (IL-15), a cytokine involved in immune-mediated pathways.

Vitiligo is a chronic autoimmune skin disease characterized by the loss of pigment-producing cells, affecting people of all ages and ethnicities. Current treatment options are limited, highlighting the need for systemic therapies. TEV-‘408 aims to reduce immune-mediated destruction of melanocytes in vitiligo and IL-15-driven intestinal inflammation in celiac disease. Royalty Pharma is the largest buyer of biopharmaceutical royalties and collaborates with innovators to fund transformative therapies. Teva is focused on becoming a leading innovative biopharmaceutical company, dedicated to addressing patients’ needs worldwide.

Read more at GlobeNewswire: Royalty Pharma and Teva Enter Agreement to Accelerate